Johnson & Johnson is Banking on Therapeutics as Device Biz Growth Slows

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Johnson & Johnson has traditionally had a strong medical device and diagnostics sectors but the growth in both of those areas has slowed. In the second quarter of 2013, the device segment grew at a rate of 0.5%—ignoring the Synthes acquisition and currency fluctuations. The company is rumored to be mulling the sale of its Ortho Clinical Diagnostics division. Still, the device diagnostic segments are vital for the firm, compromising 41% of its 2012 revenue.

Help employers find you! Check out all the jobs and post your resume.

Back to news